Evidence map›Paper›PMID 35521944›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2022

Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease.

Shijie Wang, Shakthi Unnithan, Nicole Bryant, Allison Chang, Liana S Rosenthal, Alexander Pantelyat, Ted M Dawson, Hussein R Al-Khalidi, Andrew B West

Open access · hybridAbstract read
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. LRRK2 as a Potential Disease-Modifying Target in Sporadic Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Rab10-CAV1 mediated intraluminal vesicle transport to migrasomes.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. LRRK2-Targeting Therapies March Through the Valley of Death.Movement disorders : official journal of the Movement Disorder Society · 2023
    Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Shijie WangDuke Center for Neurodegeneration and Neurotherapeutics, Duke University, Durham, North Carolina, USA.
Shakthi UnnithanDepartment of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA.
Nicole BryantDuke Center for Neurodegeneration and Neurotherapeutics, Duke University, Durham, North Carolina, USA.
Allison ChangDuke Center for Neurodegeneration and Neurotherapeutics, Duke University, Durham, North Carolina, USA.
Liana S RosenthalDepartment of Neurology, The Johns Hopkins University, Baltimore, Maryland, USA.
Alexander PantelyatDepartment of Neurology, The Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0002-6427-7485
Ted M DawsonDepartment of Neurology, The Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0002-6459-0893
Hussein R Al-KhalidiDepartment of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA.
Andrew B WestDuke Center for Neurodegeneration and Neurotherapeutics, Duke University, Durham, North Carolina, USA.ORCID 0000-0002-3034-4061
Duke University · USJohns Hopkins University · US

Funding

Understanding Mechanisms of a-synuclein pathologyP50NS038377 · NINDS · JOHNS HOPKINS UNIVERSITY · PI DAWSON, TED M. · 1998 to 2019
$38.8M
Project 3: LRRK2 mediated macrophage responses in PDP50NS108675 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI STANDAERT, DAVID G. · 2018 to 2022
$9.9M
Mechanisms of LRRK2 Mediated NeurotoxicityR01NS064934 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WEST, ANDREW B · 2010 to 2025
$6.3M
Johns Hopkins Medicine Biomarker Discovery in Parkinson's DiseaseU01NS082133 · NINDS · JOHNS HOPKINS UNIVERSITY · PI DAWSON, TED M. · 2012 to 2016
$4.1M
Biomarker Discovery and Validation in Parkinson's DiseaseU01NS097049 · NINDS · JOHNS HOPKINS UNIVERSITY · PI ROSENTHAL, LIANA ISA SHAPIRO · 2017 to 2019
$1.9M
Exosome LRRK2 in Predicting Parkinson Disease PhenotypesU01NS097028 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WEST, ANDREW B · 2016 to 2018
$1.0M
NINDS NIH HHS P50 NS038377NINDS NIH HHS P50 NS108675NINDS NIH HHS R01 NS064934NINDS NIH HHS U01 NS082133NINDS NIH HHS U01 NS097028NINDS NIH HHS U01 NS097049
6 · The paper itself

Abstract

backgroundPathogenic leucine-rich repeat kinase 2 LRRK2 mutations may increase LRRK2 kinase activity and Rab substrate phosphorylation. Genetic association studies link variation in LRRK2 to idiopathic Parkinson disease (iPD) risk.

objectivesThrough measurements of the LRRK2 kinase substrate pT73-Rab10 in urinary extracellular vesicles, this study seeks to understand how LRRK2 kinase activity might change with iPD progression.

methodsUsing an immunoblotting approach validated in LRRK2 transgenic mice, the ratio of pT73-Rab10 to total Rab10 protein was measured in extracellular vesicles from a cross-section of G2019S LRRK2 mutation carriers (N = 45 participants) as well as 485 urine samples from a novel longitudinal cohort of iPD and controls (N = 85 participants). Generalized estimating equations were used to conduct analyses with commonly used clinical scales.

resultsAlthough the G2019S LRRK2 mutation did not increase pT73-Rab10 levels, the ratio of pT73-Rab10 to total Rab10 nominally increased over baseline in iPD urine vesicle samples with time, but did not increase in age-matched controls (1.34-fold vs. 1.05-fold, 95% confidence interval [CI], 0.004-0.56; P = 0.046; Welch's t test). Effect estimates adjusting for sex, age, disease duration, diagnosis, and baseline clinical scores identified increasing total Movement Disorder Society-Sponsored Revision of the Unified (MDS-UPDRS) scores (β = 0.77; CI, 0.52-1.01; P = 0.0001) with each fold increase of pT73-Rab10 to total Rab10. Lower Montreal Cognitive Assessment (MoCA) score in iPD is also associated with increased pT73-Rab10.

conclusionsThese results provide initial insights into peripheral LRRK2-dependent Rab phosphorylation, measured in biobanked urine, where higher levels of pT73-Rab10 are associated with worse disease progression. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson Movement Disorder Society.

Indexed as

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2Parkinson Diseaserab GTP-Binding ProteinsAnimalsHumansMiceMice, TransgenicMutationPhosphorylationLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanLrrk2 protein, mouseRab10 protein, humanRab10 protein, mouserab GTP-Binding ProteinsbiomarkerlongitudinalneurodegenerationPark8

Identifiers

PMID35521944
PMCPMC9308673
OpenAlexW4228998719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.